Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
    • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.

    The EU Clinical Trials Register currently displays   39467   clinical trials with a EudraCT protocol, of which   6475   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    39,258 result(s) found. Displaying page 1,786 of 1,963.
    «« First « Previous 1782  1783  1784  1785  1786  1787  1788  1789  1790  Next» Last»»
    EudraCT Number: 2010-022881-28 Sponsor Protocol Number: 1014001 Start Date*: 2015-10-01
    Sponsor Name:CHU Toulouse
    Full Title:
    Medical condition:
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003226-33 Sponsor Protocol Number: 0480 Start Date*: 2018-09-13
    Sponsor Name:Dean of the Medical Faculty of the Friedrich-Alexander University Erlangen-Nürnberg Prof. Dr. Markus Neurath
    Full Title: First-line treatment of locally advanced HNSCC with double checkpoint blockade and radiotherapy dependent on intratumoral CD8+ T cell infiltration (CheckRad-CD8)
    Medical condition: Locally advanced head and neck squamous cell carcinoma (HNSCC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10026518 Malignant neoplasm of supraglottis stage III LLT
    21.1 100000004864 10026519 Malignant neoplasm of supraglottis stage IV LLT
    21.1 100000004864 10026185 Malignant neoplasm of oropharynx, unspecified LLT
    21.0 100000004864 10041862 Squamous cell carcinoma of the oral cavity stage III LLT
    21.0 100000004864 10041863 Squamous cell carcinoma of the oral cavity stage IV LLT
    21.0 100000004864 10041854 Squamous cell carcinoma of the hypopharynx stage III LLT
    21.0 100000004864 10041855 Squamous cell carcinoma of the hypopharynx stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004387-35 Sponsor Protocol Number: MK-3475-775/E7080-G000-309 Start Date*: 2018-06-13
    Sponsor Name:Eisai Ltd
    Full Title: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Pembrolizumab Versus Treatment of Physician’s Choice in Participants with A...
    Medical condition: Advanced Endometrial Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014733 Endometrial cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Ongoing) ES (Ongoing) IE (Ongoing) GB (GB - no longer in EU/EEA) PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003150-16 Sponsor Protocol Number: COUP-1 Start Date*: 2018-11-21
    Sponsor Name:University Hospital Ulm
    Full Title: Copanlisib and Rituximab in Marginal Zone Lymphoma Patients
    Medical condition: Marginal Zone Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062113 Splenic marginal zone lymphoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076596 Marginal zone lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003380-35 Sponsor Protocol Number: EX9536-4388 Start Date*: 2018-10-05
    Sponsor Name:Novo Nordisk A/S
    Full Title: SELECT - Semaglutide effects on cardiovascular outcomes in people with overweight or obesity
    Medical condition: Overweight Obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10033307 Overweight PT
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Ongoing) DK (Ongoing) FI (Ongoing) IE (Ongoing) PT (Ongoing) GB (GB - no longer in EU/EEA) LV (Ongoing) NL (Ongoing) CZ (Ongoing) HU (Ongoing) BE (Ongoing) AT (Ongoing) SE (Ongoing) HR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-001643-39 Sponsor Protocol Number: 2215-CL-0302 Start Date*: 2017-02-09
    Sponsor Name:Astellas Pharma Global Development, Inc. (APGD)
    Full Title: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo- Controlled Trial of the FLT3 Inhibitor Gilteritinib (ASP2215) Administered as Maintenance Therapy Following Induction/Consolidation Therapy...
    Medical condition: Subjects diagnosed with FLT3/ITD acute myeloid leukemia (AML) in CR1, including CRp and CRi, for whom a decision not to proceed with transplantation has been made, or a suitable donor could not be ...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Ongoing) ES (Ongoing) CZ (Completed) PL (Ongoing) PT (Ongoing) SE (Ongoing) GR (Ongoing) DK (Ongoing) HR (Ongoing) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004451-70 Sponsor Protocol Number: NOR-GRASPALL-2016 Start Date*: 2017-04-06
    Sponsor Name:Department of pediatrics, Aarhus University Hospital
    Full Title: NOR-GRASPALL 2016: SINGLE-ARM PHARMACOKINETIC/PHARMACODYNAMIC AND SAFETY STUDY OF ERYASPASE (GRASPA®) FOR PATIENTS WITH HYPERSENSITIVITY TO PEG-ASPARAGINASE, DIAGNOSED WITH PH(-) ACUTE LYMPHOBLASTI...
    Medical condition: Patients with acute lymphoblastic leukemia with allergy against PEG-asparaginase
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DK (Completed) NO (Completed) FI (Completed) SE (Completed) EE (Completed) LT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001834-25 Sponsor Protocol Number: MasterDapt Start Date*: 2017-11-07
    Sponsor Name:ECRI-9
    Full Title: MAnagement of high bleeding risk patients post bioresorbable polymer coated STEnt implantation with an abbReviated versus prolonged DAPT regimen – MASTER DAPT
    Medical condition: High bleeding risk population represents a significant proportion of coronary artery disease (CAD) patients undergoing coronary stent implantation. Decisions regarding the duration of dual antiplat...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007541 Cardiac disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing) ES (Ongoing) SE (Ongoing) DE (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001616-11 Sponsor Protocol Number: DSMM_XVII Start Date*: 2018-06-25
    Sponsor Name:University Hospital Wuerzburg
    Full Title: Elotuzumab (E) in Combination with Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) versus KRd prior to and following Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma and Subs...
    Medical condition: Newly Diagnosed Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003521-21 Sponsor Protocol Number: GLPG2737-CL-203 Start Date*: 2020-01-20
    Sponsor Name:Galapagos NV
    Full Title: An exploratory, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, tolerability and pharmacokinetics of orally administered GLPG2737 for 52 weeks, in ...
    Medical condition: Autosomal dominant polycystic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10036046 Polycystic kidney, autosomal dominant LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Ongoing) NL (Ongoing) DE (Ongoing) ES (Ongoing) CZ (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-002668-28 Sponsor Protocol Number: HP-301 Start Date*: 2020-04-21
    Sponsor Name:Phathom Pharmaceuticals, Inc.
    Full Title: A Phase 3 Randomized Multicenter Study to Evaluate the Efficacy and Safety of Open-Label Dual Therapy with Oral Vonoprazan 20 mg or Double-Blind Triple Therapy with Oral Vonoprazan 20 mg Compared t...
    Medical condition: Helicobacter pylori infection
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004862 10019377 Helicobacter pylori infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Ongoing) GB (GB - no longer in EU/EEA) CZ (Ongoing) BG (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-000246-34 Sponsor Protocol Number: 7655A-014 Start Date*: 2015-09-28
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/T...
    Medical condition: Treatment for hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) EE (Completed) LV (Completed) BG (Completed) PT (Completed) LT (Completed) FR (Completed) ES (Completed) HR (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-001564-30 Sponsor Protocol Number: RA101495-02.301 Start Date*: 2019-10-29
    Sponsor Name:Ra Pharmaceuticals, Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double Blind, Placebo-Controlled Study to Confirm the Safety, Tolerability, and Efficacy of Zilucoplan in Subjects with Generalized Myasthenia Gravis
    Medical condition: Generalized Myasthenia Gravis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10028415 Myasthenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-000734-30 Sponsor Protocol Number: D0816C00012 Start Date*: 2015-07-10
    Sponsor Name:AstraZeneca AB
    Full Title: An Open Label, Single Arm, Multicentre Study to Assess the Clinical Effectiveness and Safety of Lynparza (Olaparib) Capsules Maintenance Monotherapy in Platinum Sensitive Relapsed somatic or germli...
    Medical condition: BRCA or HRR+ Mutated Ovarian Cancer Patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Ongoing) ES (Ongoing) HU (Ongoing) BG (Ongoing) PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004190-13 Sponsor Protocol Number: TX05-03 Start Date*: 2018-02-08
    Sponsor Name:Tanvex Biologics Corp.
    Full Title: A randomized, double-blind, parallel group, Phase III trial to compare the efficacy, safety, and immunogenicity of TX05 with Herceptin® in subjects with HER2 positive early breast cancer
    Medical condition: HER-2 positive breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) BG (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-004095-19 Sponsor Protocol Number: TIO-II-19-1 Start Date*: 2020-02-03
    Sponsor Name:Laboratoires SMB S.A.
    Full Title: A pharmacodynamic, randomised, single dose, cross-over study to compare the bronchodilator effect of a new formulation of Tiotropium DPI versus Spiriva® 18 μg Handihaler®
    Medical condition: Chronic obstructive pulmonary disease (bronchodilating effect)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002108-41 Sponsor Protocol Number: MT-1186-A01 Start Date*: 2020-05-06
    Sponsor Name:Mitsubishi Tanabe Pharma Development America, Inc.
    Full Title: A Phase 3, Multi-center, Open-label, Safety Study of Oral Edaravone Administered over 48 Weeks in Subjects with Amyotrophic Lateral Sclerosis (ALS)
    Medical condition: Amyotrophic Lateral Sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-000506-37 Sponsor Protocol Number: ECWM-1 Start Date*: 2014-10-31
    Sponsor Name:University Hospital Ulm
    Full Title: Efficacy of first line Dexamethasone, Rituximab and Cyclophosphamide (DRC) +/- Bortezomib for patients with Waldenström's Macroglobulinemia
    Medical condition: Waldenström's Macroglobulinemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Ongoing) IT (Ongoing) PT (Prematurely Ended) SE (Ongoing) GR (Restarted) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-003609-80 Sponsor Protocol Number: ECASS-4:ExTEND Start Date*: 2014-01-23
    Sponsor Name:Ruprecht-Karls-University Heidelberg, Medical Faculty
    Full Title: European Cooperative Acute Stroke Study-4: Extending the time for thrombolysis in emergency neurological deficits.
    Medical condition: Acute Ischemic Stroke
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) AT (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) CZ (Prematurely Ended) IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2012-004322-24 Sponsor Protocol Number: ARN-509-003 Start Date*: 2013-08-27
    Sponsor Name:Aragon Pharmaceuticals, Inc
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer
    Medical condition: Castration-Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: AT (Ongoing) FI (Ongoing) SE (Ongoing) NL (Ongoing) BE (Ongoing) IT (Ongoing) NO (Completed) DE (Ongoing) ES (Ongoing) PL (Ongoing) DK (Ongoing) HU (Ongoing) SK (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 1782  1783  1784  1785  1786  1787  1788  1789  1790  Next» Last»»
    Query did not match any studies.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2021 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands     Legal notice
    EMA HMA